NCT04417582

Brief Summary

In this is an observational study, obese patients that administed and followed in endocrinology clinic of Marmara University Medical school hospital will follow for clinical and laboratory parameters prospectively for 5 years

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 2, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 4, 2020

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

June 4, 2020

Status Verified

June 1, 2020

Enrollment Period

3.9 years

First QC Date

June 2, 2020

Last Update Submit

June 3, 2020

Conditions

ObesityWeight Change, BodyObesity; EndocrineObesity, Metabolically Benign

Keywords

obesityweight loss

Outcome Measures

Primary Outcomes (3)

  • weight loss

    %5-10 weight loss

    6 months interval

  • metabolic improvement

    blood glucose

    6 months interval

  • metabolic improvement

    serum lipid levels

    6 month

Study Arms (3)

life syte modification only

obese patients followed with life style modification

Procedure: bariatric surgey

medical teatment with antiobesity drugs

patients prescribed antiobesity drugs

Procedure: bariatric surgey

bariatric surgery

patients undergone bariatric surgery

Interventions

bariatric surgeyPROCEDURE

patients undergone bariatric surgery or prescribed antiobesity drugs

Also known as: antiobesity drugs ,liraglutide or orlistat
life syte modification onlymedical teatment with antiobesity drugs

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

obese patients refered to our tertiary center for obesity evaluation or treatment

You may qualify if:

  • Body mass index over 30 kg/m2 age between 18-65 years

You may not qualify if:

  • active malignancy pregnancy during involvement period chronic inflamatuar diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marmara University Medical School Section of Endocrinology and Metabolism

Istanbul, 34899, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

ObesityBody Weight ChangesObesity, Metabolically BenignWeight Loss

Interventions

Orlistat

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

LactonesOrganic Chemicals

Central Study Contacts

Dilek Gogas Yavuz, MD

CONTACT

+902166254685dilekgogas@marmara.edu.tr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 2, 2020

First Posted

June 4, 2020

Study Start

January 1, 2020

Primary Completion

December 1, 2023

Study Completion

December 1, 2025

Last Updated

June 4, 2020

Record last verified: 2020-06

Locations

TU(1)